We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
Fields »
 

Field

Term
Gene name

Class

Subclass

Chromosome

External id

In atlas

Reliability

Reliability

Reliability

Validation

Method

Validation

Method

Validation

Method

Validation

Location

Searches

Tissue

Cell type

Expression

Tissue

Specificity

Cell line

Specificity

Cancer

Specificity

Tissue

Detectable

Cell line

Detectable

Cancer

Detectable

Cancer

Prognosis

Category

Score

Score

Score

Antibodies

Column

 
 
ABOUT
HELP
BLOG
  • THE HUMAN PROTEOME
  • THE HUMAN TISSUES
  • THE HUMAN CELL
  • HUMAN PATHOLOGY
  • PROTEIN CLASSES
  • PROTEIN EVIDENCE
    • NEWS
    • BLOG
    • EVENTS
    • PRESS ROOM
    • LEARN
    • DICTIONARY
    • METHODS
    • CELL LINES
  • THE PROJECT
  • INTRODUCTION
  • ORGANIZATION
  • PUBLICATIONS
  • PUBLICATION DATA
  • ANTIBODY SUBMISSION
  • ANTIBODY AVAILABILITY
  • LINKS
  • CONTACT
  • TECHNICAL DATA
  • ANTIBODY VALIDATION
  • ASSAYS & ANNOTATION
  • DISCLAIMER
  • DOWNLOADABLE DATA
  • HELP & FAQ
  • LICENCE & CITATION
  • PRIVACY STATEMENT
  • RELEASE HISTORY
ANXA1
  • premium

    TISSUE

  • premium

    CELL

  • PATHOLOGY

PATHOLOGY ATLAS

GENE/PROTEIN

Antibody validation

Dictionary

Level of antibody staining/expression





High
Medium
Low
Not detected

GENERAL INFORMATION

Gene namei

Gene name according to HGNC.

ANXA1

Gene descriptioni

Gene description according to HGNC.

Annexin A1

Protein classi

Protein class the gene product belongs to according to selected gene lists. List of protein classes.

Cancer-related genes
FDA approved drug targets
Plasma proteins
Predicted intracellular proteins
Transporters

Predicted localizationi

Protein localization predicted from several bioinformatic algorithms.

Read more

Intracellular

Number of transcriptsi

Number of protein-coding transcribed from this gene as defined by Ensembl.

4
SHOW MORE

HUMAN PROTEIN ATLAS INFORMATION

RNA categoryi

RNA category is based on mRNA expression levels in the analyzed samples (RNA assay description). The categories include: tissue/cell line enriched, group enriched, tissue/cell line enhanced, expressed in all, mixed and not detected. RNA category is calculated separately for The Cancer Genome Atlas (TCGA) data from cancer tissues and internally generated Human Protein Atlas (HPA) data from normal tissues and cell lines.

TCGA (cancer tissue):Expressed in all
HPA (cell line):Mixed
HPA (normal tissue):Tissue enriched (esophagus)

Protein evidencei

Protein evidence scores are generated from several independent sources and are classified as evidence at i) protein level, ii) transcript level, iii) no evidence, or iv) not available.

Evidence at protein level

Protein expression
normal tissuei

A summary of the overall protein expression pattern across the analyzed normal tissues. The summary is based on knowledge-based annotation.

"Estimation of protein expression could not be performed. View primary data." is shown for genes analyzed with a knowledge-based approach where available RNA-seq and gene/protein characterization data has been evaluated as not sufficient in combination with immunohistochemistry data to yield a reliable estimation of the protein expression profile.

Read more

Cytoplasmic, membranous and nuclear expression at variable levels in selected tissues.

ANTIBODY IHC RELIABILITY

Data reliability
descriptioni

Standardized explanatory sentences with additional information required for full understanding of the knowledge-based expression profile.

Antibody staining mainly consistent with RNA expression data.

Reliability scorei

Reliability score (score description), divided into Supported, Approved, or Uncertain, is evaluated in normal tissues and based on consistency between the staining pattern of one antibody or several antibodies with RNA-seq data and available gene/protein characterization data.

Read more

Supported based on 5 antibodies.
HPA011271 , HPA011272 , CAB013023 , CAB035987 , CAB058693
SHOW MORE

PROGNOSTIC SUMMARYi

Kaplan-Meier plots for all cancers where high expression of this gene has significant (p<0.001) association with patient survival are shown in this summary. Whether the prognosis is favourable or unfavourable is indicated in brackets. Each Kaplan-Meier plot is clickable and redirects to a detailed page that includes individual expression and survival data for patients with the selected cancer.

Prognostic marker in urothelial cancer (unfavourable), thyroid cancer (favourable) and endometrial cancer (favourable).
Urothelial cancer p<0.001
Thyroid cancer p<0.001
Endometrial cancer p<0.001
Show all

RNA EXPRESSION OVERVIEWi

RNA expression overview shows RNA-seq data from The Cancer Genome Atlas (TCGA).

TCGA dataseti
RNA-seq data in 17 cancer types are reported as median FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA). RNA cancer tissue category is calculated based on mRNA expression levels across all 17 cancer tissues and include: cancer tissue enriched, cancer group enriched, cancer tissue enhanced, expressed in all, mixed and not detected. To access cancer specific RNA and prognostic data, click on the cancer name.

Read more
RNA cancer category: Expressed in all

PROTEIN EXPRESSIONi

Antibody staining in 20 different cancers is summarized by a selection of four standard cancer tissue samples representative of the overall staining pattern. From left: colorectal cancer, breast cancer, prostate cancer and lung cancer. An additional fifth image can be added as a complement. The assay and annotation is described here. Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.

For histological reference, visit the histological dictionary.

Colorectal cancer
Breast cancer
Prostate cancer
Lung cancer

STAINING SUMMARYi

For each cancer, the fraction of samples with protein expression level high, medium, low, or not detected are provided by the blue-scale color-coding (as described by the color-coding scale in the box to the left). The length of the bar represents the number of patient samples analyzed (max=12 patients). The images and annotations can be accessed by clicking on the cancer name or protein expression bar. If more than one antibody is analyzed, the tabs at the top of the staining summary section can be used to toggle between the different antibodies. The mouse-over function displays additional data for the features in the staining summary view.

Next to the cancer staining data, the protein expression data of normal tissues or specific cell types corresponding to each cancer are shown and protein expression levels are indicated by the blue-scale color coding.

HPA011271
HPA011272
CAB013023
CAB035987
CAB058693

Cancer

Cancer staining

Protein
expression of
normal tissue

Breast cancer
 
Carcinoid
 
Cervical cancer
 
 
Colorectal cancer
 
 
Endometrial cancer
 
 
Glioma
 
Head and neck cancer
 
 
Liver cancer
 
 
Lung cancer
 
 
Lymphoma
 
 
 

Cancer

Cancer staining

Protein
expression of
normal tissue

Melanoma
 
Ovarian cancer
 
Pancreatic cancer
 
Prostate cancer
 
Renal cancer
 
Skin cancer
 
Stomach cancer
 
 
Testis cancer
 
Thyroid cancer
 
Urothelial cancer
 

Staining summaryi

A manually written summary of the overall protein expression pattern across the analyzed cancer tissues.

Thyroid cancers along with several cases of malignant melanomas, cancers of female genitalia, lung, skin and urothelia displayed moderate to strong cytoplasmic immunoreactivity, in several cases combined with membranous staining and in a few nuclear positivity. Malignant cells in general were negative. Most pancreatic and several renal cancers were moderately stained.

Cancer

Cancer staining

Protein
expression of
normal tissue

Breast cancer
 
Carcinoid
 
Cervical cancer
 
 
Colorectal cancer
 
 
Endometrial cancer
 
 
Glioma
 
Head and neck cancer
 
 
Liver cancer
 
 
Lung cancer
 
 
Lymphoma
 
 
 

Cancer

Cancer staining

Protein
expression of
normal tissue

Melanoma
 
Ovarian cancer
 
Pancreatic cancer
 
Prostate cancer
 
Renal cancer
 
Skin cancer
 
Stomach cancer
 
 
Testis cancer
 
Thyroid cancer
 
Urothelial cancer
 

Staining summaryi

A manually written summary of the overall protein expression pattern across the analyzed cancer tissues.

Squamous cell carcinomas, malignant melanomas, female genital cancers, urothelial, thyroid and pancreatic cancers displayed moderate to strong cytoplasmic immunoreactivity often combined with nuclear and membranous positivity. Remaining malignancies were in general negative.

Cancer

Cancer staining

Protein
expression of
normal tissue

Breast cancer
 
Carcinoid
 
Cervical cancer
 
 
Colorectal cancer
 
 
Endometrial cancer
 
 
Glioma
 
Head and neck cancer
 
 
Liver cancer
 
 
Lung cancer
 
 
Lymphoma
 
 
 

Cancer

Cancer staining

Protein
expression of
normal tissue

Melanoma
 
Ovarian cancer
 
Pancreatic cancer
 
Prostate cancer
 
Renal cancer
 
Skin cancer
 
Stomach cancer
 
 
Testis cancer
 
Thyroid cancer
 
Urothelial cancer
 

Staining summaryi

A manually written summary of the overall protein expression pattern across the analyzed cancer tissues.

Most malignant cells displayed moderate to strong cytoplasmic and nuclear positivity. Hepatocellular carcinomas, basal cell carcinomas, breast cancers and malignant lymphomas were mainly weakly stained or negative.

Cancer

Cancer staining

Protein
expression of
normal tissue

Breast cancer
 
Carcinoid
 
Cervical cancer
 
 
Colorectal cancer
 
 
Endometrial cancer
 
 
Glioma
 
Head and neck cancer
 
 
Liver cancer
 
 
Lung cancer
 
 
Lymphoma
 
 
 

Cancer

Cancer staining

Protein
expression of
normal tissue

Melanoma
 
Ovarian cancer
 
Pancreatic cancer
 
Prostate cancer
 
Renal cancer
 
Skin cancer
 
Stomach cancer
 
 
Testis cancer
 
Thyroid cancer
 
Urothelial cancer
 

Staining summaryi

A manually written summary of the overall protein expression pattern across the analyzed cancer tissues.

Female genital, thyroid and urothelial cancers along with some cases of malignant melanomas, lung, skin and pancreatic cancers showed strong positivity. Remaining malignancies were weakly stained or negative.

Cancer

Cancer staining

Protein
expression of
normal tissue

Breast cancer
 
Carcinoid
 
Cervical cancer
 
 
Colorectal cancer
 
 
Endometrial cancer
 
 
Glioma
 
Head and neck cancer
 
 
Liver cancer
 
 
Lung cancer
 
 
Lymphoma
 
 
 

Cancer

Cancer staining

Protein
expression of
normal tissue

Melanoma
 
Ovarian cancer
 
Pancreatic cancer
 
Prostate cancer
 
Renal cancer
 
Skin cancer
 
Stomach cancer
 
 
Testis cancer
 
Thyroid cancer
 
Urothelial cancer
 

Staining summaryi

A manually written summary of the overall protein expression pattern across the analyzed cancer tissues.

A majority of cancer tissues exhibited moderate to strong cytoplasmic and nuclear positivity with additional membranous positivity in a few cases. Lymphomas, carcinoid, breast and testicular cancers along with several cases of gliomas, colorectal, renal, stomach and liver cancers were negative.

GENE INFORMATIONi

Gene information from Ensembl and Entrez, as well as links to available gene identifiers are displayed here. Information was retrieved from Ensembl if not indicated otherwise.

Gene name

ANXA1 (HGNC Symbol)

Synonyms

ANX1, LPC1

Description

Annexin A1 (HGNC Symbol)

Entrez gene summary

This gene encodes a membrane-localized protein that binds phospholipids. This protein inhibits phospholipase A2 and has anti-inflammatory activity. Loss of function or expression of this gene has been detected in multiple tumors. [provided by RefSeq, Dec 2014]

Chromosome

9

Cytoband

q21.13

Chromosome location (bp)

73151757 - 73170393

Protein evidence

Evidence at protein level (all genes)

Ensembl

ENSG00000135046 (version 83.38)

Entrez gene

301

UniProt

P04083 (UniProt - Evidence at protein level)

neXtProt

NX_P04083

Antibodypedia

ANXA1 antibodies

PROTEIN BROWSERi

The protein browser displays the antigen location on the target protein(s) and the features of the target protein. The tabs at the top of the protein view section can be used to switch between the different splice variants to which an antigen has been mapped.

At the top of the view, the position of the antigen (identified by the corresponding HPA identifier) is shown as a green bar. A yellow triangle on the bar indicates a <100% sequence identity to the protein target.

Under the antigens, the maximum percent sequence identity of the protein to all other proteins from other human genes is displayed, using a sliding window of 10 aa residues (HsID 10) or 50 aa residues (HsID 50) (read more).

If a signal peptide is predicted by a majority of the signal peptide predictors SPOCTOPUS, SignalP 4.0, and Phobius (turquoise) and/or transmembrane regions (orange) are predicted by MDM, these are displayed.

Low complexity regions are shown in yellow and InterPro regions in green. Common (purple) and unique (grey) regions between different splice variants of the gene are also displayed (read more), and at the bottom of the protein view is the protein scale.

ANXA1-002
ANXA1-003
ANXA1-004
ANXA1-006

PROTEIN INFORMATIONi

The protein information section displays alternative protein-coding transcripts (splice variants) encoded by this gene according to the Ensembl database.

The ENSP identifier links to the Ensembl website protein summary, while the ENST identifier links to the Ensembl website transcript summary for the selected splice variant. The data in the UniProt column can be expanded to show links to all matching UniProt identifiers for this protein.

The protein classes assigned to this protein are shown if expanding the data in the protein class column. Parent protein classes are in bold font and subclasses are listed under the parent class.

The Gene Ontology terms assigned to this protein are listed if expanding the Gene ontology column. The length of the protein (amino acid residues according to Ensembl), molecular mass (kDalton), predicted signal peptide (according to a majority of the signal peptide predictors SPOCTOPUS, SignalP 4.0, and Phobius) and the number of predicted transmembrane region(s) (according to MDM) are also reported.

Splice variant

UniProt

Protein class

Gene ontology

Length & mass

Signal peptide
(predicted)

Transmembrane regions
(predicted)

ANXA1-002
ENSP00000257497
ENST00000257497
P04083 [Direct mapping]
Annexin A1
Q5TZZ9 [Target identity:100%; Query identity:100%]
Annexin
Show all
Transporters
   Transporter channels and pores
Predicted intracellular proteins
Plasma proteins
Cancer-related genes
   Candidate cancer biomarkers
FDA approved drug targets
   Small molecule drugs
Protein evidence (Kim et al 2014)
Protein evidence (Ezkurdia et al 2014)
Show all
GO:0001533 [cornified envelope]
GO:0001780 [neutrophil homeostasis]
GO:0002548 [monocyte chemotaxis]
GO:0002685 [regulation of leukocyte migration]
GO:0005102 [receptor binding]
GO:0005198 [structural molecule activity]
GO:0005509 [calcium ion binding]
GO:0005515 [protein binding]
GO:0005543 [phospholipid binding]
GO:0005544 [calcium-dependent phospholipid binding]
GO:0005576 [extracellular region]
GO:0005615 [extracellular space]
GO:0005634 [nucleus]
GO:0005737 [cytoplasm]
GO:0005768 [endosome]
GO:0005886 [plasma membrane]
GO:0005925 [focal adhesion]
GO:0006909 [phagocytosis]
GO:0006954 [inflammatory response]
GO:0007165 [signal transduction]
GO:0007187 [G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger]
GO:0008360 [regulation of cell shape]
GO:0009986 [cell surface]
GO:0016323 [basolateral plasma membrane]
GO:0016324 [apical plasma membrane]
GO:0016328 [lateral plasma membrane]
GO:0018149 [peptide cross-linking]
GO:0019834 [phospholipase A2 inhibitor activity]
GO:0019898 [extrinsic component of membrane]
GO:0030216 [keratinocyte differentiation]
GO:0030674 [protein binding, bridging]
GO:0031232 [extrinsic component of external side of plasma membrane]
GO:0031313 [extrinsic component of endosome membrane]
GO:0031340 [positive regulation of vesicle fusion]
GO:0031514 [motile cilium]
GO:0031532 [actin cytoskeleton reorganization]
GO:0031901 [early endosome membrane]
GO:0031982 [vesicle]
GO:0032652 [regulation of interleukin-1 production]
GO:0032743 [positive regulation of interleukin-2 production]
GO:0042102 [positive regulation of T cell proliferation]
GO:0043066 [negative regulation of apoptotic process]
GO:0045627 [positive regulation of T-helper 1 cell differentiation]
GO:0045629 [negative regulation of T-helper 2 cell differentiation]
GO:0045920 [negative regulation of exocytosis]
GO:0046632 [alpha-beta T cell differentiation]
GO:0046883 [regulation of hormone secretion]
GO:0048306 [calcium-dependent protein binding]
GO:0050727 [regulation of inflammatory response]
GO:0070062 [extracellular exosome]
GO:0071385 [cellular response to glucocorticoid stimulus]
GO:0071621 [granulocyte chemotaxis]
GO:0090303 [positive regulation of wound healing]
GO:0097350 [neutrophil clearance]
GO:2000483 [negative regulation of interleukin-8 secretion]
Show all
346 aa
38.7 kDa
No 0
ANXA1-003
ENSP00000366109
ENST00000376911
P04083 [Direct mapping]
Annexin A1
Q5TZZ9 [Target identity:100%; Query identity:100%]
Annexin
Show all
Transporters
   Transporter channels and pores
Predicted intracellular proteins
Plasma proteins
Cancer-related genes
   Candidate cancer biomarkers
FDA approved drug targets
   Small molecule drugs
Protein evidence (Ezkurdia et al 2014)
Show all
GO:0000733 [DNA strand renaturation]
GO:0001533 [cornified envelope]
GO:0001780 [neutrophil homeostasis]
GO:0002548 [monocyte chemotaxis]
GO:0002685 [regulation of leukocyte migration]
GO:0003697 [single-stranded DNA binding]
GO:0003727 [single-stranded RNA binding]
GO:0004386 [helicase activity]
GO:0005102 [receptor binding]
GO:0005198 [structural molecule activity]
GO:0005509 [calcium ion binding]
GO:0005515 [protein binding]
GO:0005543 [phospholipid binding]
GO:0005544 [calcium-dependent phospholipid binding]
GO:0005576 [extracellular region]
GO:0005615 [extracellular space]
GO:0005634 [nucleus]
GO:0005737 [cytoplasm]
GO:0005768 [endosome]
GO:0005886 [plasma membrane]
GO:0005925 [focal adhesion]
GO:0006909 [phagocytosis]
GO:0006954 [inflammatory response]
GO:0007165 [signal transduction]
GO:0007166 [cell surface receptor signaling pathway]
GO:0007187 [G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger]
GO:0008360 [regulation of cell shape]
GO:0009725 [response to hormone]
GO:0009986 [cell surface]
GO:0010165 [response to X-ray]
GO:0014070 [response to organic cyclic compound]
GO:0014839 [myoblast migration involved in skeletal muscle regeneration]
GO:0016323 [basolateral plasma membrane]
GO:0016324 [apical plasma membrane]
GO:0016328 [lateral plasma membrane]
GO:0018149 [peptide cross-linking]
GO:0019834 [phospholipase A2 inhibitor activity]
GO:0019898 [extrinsic component of membrane]
GO:0030073 [insulin secretion]
GO:0030216 [keratinocyte differentiation]
GO:0030674 [protein binding, bridging]
GO:0030850 [prostate gland development]
GO:0031018 [endocrine pancreas development]
GO:0031232 [extrinsic component of external side of plasma membrane]
GO:0031313 [extrinsic component of endosome membrane]
GO:0031340 [positive regulation of vesicle fusion]
GO:0031394 [positive regulation of prostaglandin biosynthetic process]
GO:0031514 [motile cilium]
GO:0031532 [actin cytoskeleton reorganization]
GO:0031901 [early endosome membrane]
GO:0031960 [response to corticosteroid]
GO:0031966 [mitochondrial membrane]
GO:0031982 [vesicle]
GO:0032355 [response to estradiol]
GO:0032508 [DNA duplex unwinding]
GO:0032652 [regulation of interleukin-1 production]
GO:0032743 [positive regulation of interleukin-2 production]
GO:0033031 [positive regulation of neutrophil apoptotic process]
GO:0033676 [double-stranded DNA-dependent ATPase activity]
GO:0036292 [DNA rewinding]
GO:0036310 [annealing helicase activity]
GO:0042063 [gliogenesis]
GO:0042102 [positive regulation of T cell proliferation]
GO:0042127 [regulation of cell proliferation]
GO:0042383 [sarcolemma]
GO:0042493 [response to drug]
GO:0042629 [mast cell granule]
GO:0042803 [protein homodimerization activity]
GO:0043065 [positive regulation of apoptotic process]
GO:0043066 [negative regulation of apoptotic process]
GO:0043234 [protein complex]
GO:0043434 [response to peptide hormone]
GO:0044849 [estrous cycle]
GO:0045627 [positive regulation of T-helper 1 cell differentiation]
GO:0045629 [negative regulation of T-helper 2 cell differentiation]
GO:0045920 [negative regulation of exocytosis]
GO:0046632 [alpha-beta T cell differentiation]
GO:0046883 [regulation of hormone secretion]
GO:0048306 [calcium-dependent protein binding]
GO:0050482 [arachidonic acid secretion]
GO:0050709 [negative regulation of protein secretion]
GO:0050727 [regulation of inflammatory response]
GO:0051384 [response to glucocorticoid]
GO:0070062 [extracellular exosome]
GO:0070301 [cellular response to hydrogen peroxide]
GO:0070365 [hepatocyte differentiation]
GO:0070459 [prolactin secretion]
GO:0070555 [response to interleukin-1]
GO:0071385 [cellular response to glucocorticoid stimulus]
GO:0071621 [granulocyte chemotaxis]
GO:0090303 [positive regulation of wound healing]
GO:0097350 [neutrophil clearance]
GO:1900087 [positive regulation of G1/S transition of mitotic cell cycle]
GO:1900138 [negative regulation of phospholipase A2 activity]
GO:2000483 [negative regulation of interleukin-8 secretion]
Show all
346 aa
38.7 kDa
No 0
ANXA1-004
ENSP00000412489
ENST00000456643
Q5T3N1 [Direct mapping]
Annexin
Show all
Predicted intracellular proteins
Protein evidence (Ezkurdia et al 2014)
Show all
GO:0004859 [phospholipase inhibitor activity]
GO:0005509 [calcium ion binding]
GO:0005544 [calcium-dependent phospholipid binding]
GO:0005737 [cytoplasm]
GO:0005886 [plasma membrane]
GO:0043086 [negative regulation of catalytic activity]
Show all
204 aa
22.8 kDa
No 0
ANXA1-006
ENSP00000414013
ENST00000415424
Q5T3N0 [Direct mapping]
Annexin
Show all
Predicted intracellular proteins
Protein evidence (Ezkurdia et al 2014)
Show all
GO:0004859 [phospholipase inhibitor activity]
GO:0005509 [calcium ion binding]
GO:0005544 [calcium-dependent phospholipid binding]
GO:0005737 [cytoplasm]
GO:0005886 [plasma membrane]
GO:0043086 [negative regulation of catalytic activity]
Show all
115 aa
12.6 kDa
No 0

Contact

  • BLOG
  • PRESS ROOM
  • contact@proteinatlas.org

The Project

  • INTRODUCTION
  • ORGANIZATION
  • PUBLICATIONS
  • DOWNLOADABLE DATA

The Human Protein Atlas

  • ANTIBODY AVAILABILITY
  • LICENCE & CITATION
  • HELP & FAQ
The Human Protein Atlas project is funded
by the Knut & Alice Wallenberg foundation.